WO2004042390A3 - Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b) - Google Patents

Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b) Download PDF

Info

Publication number
WO2004042390A3
WO2004042390A3 PCT/EP2003/011881 EP0311881W WO2004042390A3 WO 2004042390 A3 WO2004042390 A3 WO 2004042390A3 EP 0311881 W EP0311881 W EP 0311881W WO 2004042390 A3 WO2004042390 A3 WO 2004042390A3
Authority
WO
WIPO (PCT)
Prior art keywords
pde4b
diseases
disorders
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2003/011881
Other languages
French (fr)
Other versions
WO2004042390A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Priority to AU2003283303A priority Critical patent/AU2003283303A1/en
Publication of WO2004042390A2 publication Critical patent/WO2004042390A2/en
Publication of WO2004042390A3 publication Critical patent/WO2004042390A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human PDE4B which is associated with the disorders of the peripheral and central nervous system (eg.Alzheimer), cardiovascular diseases, hematological diseases (eg.liver cirrhosis), respiratory diseases (eg.lung tumor) and gastroenterological disorders (eg.stomach tumor). The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, respiratory diseases and gastroenterological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE4B as well as pharmaceutical compositions comprising such compounds.
PCT/EP2003/011881 2002-11-08 2003-10-25 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b) WO2004042390A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003283303A AU2003283303A1 (en) 2002-11-08 2003-10-25 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02024995 2002-11-08
EP02024995.9 2002-11-08

Publications (2)

Publication Number Publication Date
WO2004042390A2 WO2004042390A2 (en) 2004-05-21
WO2004042390A3 true WO2004042390A3 (en) 2004-09-23

Family

ID=32309319

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/011881 WO2004042390A2 (en) 2002-11-08 2003-10-25 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)

Country Status (2)

Country Link
AU (1) AU2003283303A1 (en)
WO (1) WO2004042390A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2651474C2 (en) 2009-05-12 2018-04-19 Конинклейке Филипс Электроникс Н.В. Phosphodiesterase 4d7 as prostate cancer marker
MA38333A1 (en) 2013-02-19 2017-02-28 Pfizer Azabenzimidazole compounds as pde4 isozyme inhibitors for the treatment of disorders of snc and other conditions
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
ES2733502T3 (en) 2014-08-06 2019-11-29 Pfizer Imidazopyridazine Compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025138A2 (en) * 1998-10-23 2000-05-04 Roger Nitsch Methods of diagnosing or prognosing alzheimer's disease
US6306583B1 (en) * 1993-03-10 2001-10-23 Smithkline Beecham Corporation Human brain phosphodiesterase
WO2003016563A2 (en) * 2001-08-14 2003-02-27 Exonhit Therapeutics Sa Novel molecular target for neurotoxicity
WO2003087408A2 (en) * 2002-04-05 2003-10-23 University Court Of The University Of Edinburgh Schizophrenia associated genes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306583B1 (en) * 1993-03-10 2001-10-23 Smithkline Beecham Corporation Human brain phosphodiesterase
WO2000025138A2 (en) * 1998-10-23 2000-05-04 Roger Nitsch Methods of diagnosing or prognosing alzheimer's disease
WO2003016563A2 (en) * 2001-08-14 2003-02-27 Exonhit Therapeutics Sa Novel molecular target for neurotoxicity
WO2003087408A2 (en) * 2002-04-05 2003-10-23 University Court Of The University Of Edinburgh Schizophrenia associated genes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOLGER G ET AL: "A FAMILY OF HUMAN PHOSPHODIESTERASES HOMOLOGOUS TO THE DUNCE LEARNING AND MEMORY GENE PRODUCT OF DROSOPHILA MELANOGASTER ARE POTENTIAL TARGETS FOR ANTIDEPRESSANT DRUGS", MOLECULAR AND CELLULAR BIOLOGY, WASHINGTON, DC, US, vol. 13, no. 10, 1 October 1993 (1993-10-01), pages 6558 - 6571, XP000566626, ISSN: 0270-7306 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2002, D'SA C M ET AL: "DISTRIBUTION, CELLULAR LOCALIZATION AND REGULATION OF mRNA FOR THE cAMP - SPECIFIC PDE4B2B SPLICE VARIANT.", XP002275243, Database accession no. PREV200300269178 *
PEREZ-TORRES S ET AL: "Cellular expression of cAMP phosphodiesterase PDE4A, PDE4B and PDE4D mRNAs in Alzheimer's disease brains", ABSTRACTS OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 27, no. 1, 2001, pages 1134, XP002271232, ISSN: 0190-5295 *
SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, 32nd Annual Meeting of the Society for Neuroscience;Orlando, Florida, USA; November 02-07, 2002, pages Abstract No. 93.19 *
TAKAHASHI MICHIHIRO ET AL: "Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms", JOURNAL OF NEUROSCIENCE, vol. 19, no. 2, 15 January 1999 (1999-01-15), pages 610 - 618, XP002275242, ISSN: 0270-6474 *

Also Published As

Publication number Publication date
AU2003283303A8 (en) 2004-06-07
WO2004042390A2 (en) 2004-05-21
AU2003283303A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
WO2004042389A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
WO2003093816A3 (en) Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
WO2004042390A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
WO2004042402A3 (en) Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2004029617A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a (pde11a)
WO2003065044A8 (en) Diagnostics and therapeutics for diseases associated with gpr72
WO2004050903A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4c (pde4c)
WO2004071378A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
WO2004081563A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 1a (pde1a)
WO2004080374A3 (en) Diagnostics and therapeutics for diseases associated with phosphodi-esterase 1c (pde1c)
WO2004042387A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a1 (pde11a1)
WO2003100433A3 (en) Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (avpr3)
WO2004042077A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b)
WO2003096020A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
WO2004042391A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 10a (pde10a)
WO2004042386A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a3 (pde11a3)
WO2003100435A3 (en) Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2)
WO2004071394A3 (en) Diagnostics and therapeutics for diseases associated with hm74
WO2004075812A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 3b (pde3b)
WO2003100434A3 (en) Diagnostic and therapeutic use of the arginine vasopressin receptor 2 (avpr2)
WO2003087843A3 (en) Diagnostics and therapeutics for diseases associated with mas related gene f (mrgf)
WO2003083135A3 (en) Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)
WO2004083851A3 (en) Diagnostics and therapeutics for diseases associated with trace amine receptor 1 (ta1)
WO2004071377A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 3a (pde3a)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP